Recurrent Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2014

  • Share on Google+

Global Markets Direct

2014 Jun 30

211 Pages (PDF)




Recurrent Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2014

Summary

Global Markets Directs, Recurrent Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2014, provides an overview of the Recurrent Glioblastoma Multiforme (GBM)s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Recurrent Glioblastoma Multiforme (GBM), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Recurrent Glioblastoma Multiforme (GBM) and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Recurrent Glioblastoma Multiforme (GBM)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Recurrent Glioblastoma Multiforme (GBM) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Recurrent Glioblastoma Multiforme (GBM) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Recurrent Glioblastoma Multiforme (GBM) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Recurrent Glioblastoma Multiforme (GBM)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Recurrent Glioblastoma Multiforme (GBM) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Recurrent Glioblastoma Multiforme (GBM) Overview 10
Therapeutics Development 11
Pipeline Products for Recurrent Glioblastoma Multiforme (GBM) - Overview 11
Pipeline Products for Recurrent Glioblastoma Multiforme (GBM) - Comparative Analysis 12
Recurrent Glioblastoma Multiforme (GBM) - Therapeutics under Development by Companies 13
Recurrent Glioblastoma Multiforme (GBM) - Therapeutics under Investigation by Universities/Institutes 16
Recurrent Glioblastoma Multiforme (GBM) - Pipeline Products Glance 17
Clinical Stage Products 17
Early Stage Products 18
Recurrent Glioblastoma Multiforme (GBM) - Products under Development by Companies 19
Recurrent Glioblastoma Multiforme (GBM) - Products under Investigation by Universities/Institutes 21
Recurrent Glioblastoma Multiforme (GBM) - Companies Involved in Therapeutics Development 22
Amgen Inc. 22
AstraZeneca PLC 23
Eli Lilly and Company 24
GlaxoSmithKline plc 25
Agenus, Inc. 26
Sangamo BioSciences, Inc. 27
ZIOPHARM Oncology, Inc. 28
Novartis AG 29
Eisai Co., Ltd. 30
Ono Pharmaceutical Co., Ltd. 31
Pfizer Inc. 32
GW Pharmaceuticals plc 33
Celldex Therapeutics, Inc. 34
ImmunoCellular Therapeutics, Ltd. 35
ThromboGenics NV 36
Spectrum Pharmaceuticals, Inc. 37
Virttu Biologics Limited 38
EnGeneIC Ltd 39
AngioChem Inc. 40
GenSpera, Inc. 41
Ascenta Therapeutics, Inc. 42
Vascular Biogenics Ltd. 43
Tocagen Inc. 44
Karyopharm Therapeutics, Inc. 45
ERC Belgium SA 46
Recurrent Glioblastoma Multiforme (GBM) - Therapeutics Assessment 47
Assessment by Monotherapy Products 47
Assessment by Combination Products 48
Assessment by Target 49
Assessment by Mechanism of Action 53
Assessment by Route of Administration 57
Assessment by Molecule Type 59
Drug Profiles 61
bosutinib - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
axitinib - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
dacomitinib - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
rindopepimut - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
ortataxel - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
VB-111 - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
ANG-1005 - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
dovitinib lactate - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
AT-101 - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
G-202 - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
ARC-100 - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
buparlisib hydrochloride - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
nivolumab - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
pazopanib hydrochloride - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
galunisertib - Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
KPT-330 - Drug Profile 98
Product Description 98
Mechanism of Action 98
R&D Progress 98
G-200 - Drug Profile 100
Product Description 100
Mechanism of Action 100
R&D Progress 100
ERC-1671 - Drug Profile 102
Product Description 102
Mechanism of Action 102
R&D Progress 102
MDNA-55 - Drug Profile 104
Product Description 104
Mechanism of Action 104
R&D Progress 104
trebananib - Drug Profile 105
Product Description 105
Mechanism of Action 105
R&D Progress 105
TB-403 - Drug Profile 108
Product Description 108
Mechanism of Action 108
R&D Progress 108
nabiximols - Drug Profile 110
Product Description 110
Mechanism of Action 110
R&D Progress 110
New Castle Disease Virus - HUJ Oncolytic Virus - Drug Profile 113
Product Description 113
Mechanism of Action 113
R&D Progress 113
vocimagene amiretrorepvec + flucytosine ER - Drug Profile 114
Product Description 114
Mechanism of Action 114
R&D Progress 114
golvatinib + lenvatinib - Drug Profile 116
Product Description 116
Mechanism of Action 116
R&D Progress 116
doxorubicin - Drug Profile 118
Product Description 118
Mechanism of Action 118
R&D Progress 118
(GWP-42002 + GWP-42003) - Drug Profile 119
Product Description 119
Mechanism of Action 119
R&D Progress 119
vandetanib - Drug Profile 120
Product Description 120
Mechanism of Action 120
R&D Progress 120
ICT-121 - Drug Profile 126
Product Description 126
Mechanism of Action 126
R&D Progress 126
SB-313 - Drug Profile 127
Product Description 127
Mechanism of Action 127
R&D Progress 127
erismodegib - Drug Profile 128
Product Description 128
Mechanism of Action 128
R&D Progress 128
BTSC mRNA Loaded Dendritic Cell Vaccine - Drug Profile 130
Product Description 130
Mechanism of Action 130
R&D Progress 130
Carcinoembryonic Antigen-Expressing Measles Virus Vaccine - Drug Profile 131
Product Description 131
Mechanism of Action 131
R&D Progress 131
Ad-RTS-IL-12 - Drug Profile 132
Product Description 132
Mechanism of Action 132
R&D Progress 132
AZD-7451 - Drug Profile 134
Product Description 134
Mechanism of Action 134
R&D Progress 134
HSV-1716 - Drug Profile 135
Product Description 135
Mechanism of Action 135
R&D Progress 135
DNX-2401 - Drug Profile 137
Product Description 137
Mechanism of Action 137
R&D Progress 137
Engineered Herpes Simplex Virus Expressing Human IL-12 - Drug Profile 139
Product Description 139
Mechanism of Action 139
R&D Progress 139
OS-2966 - Drug Profile 141
Product Description 141
Mechanism of Action 141
R&D Progress 141
Recurrent Glioblastoma Multiforme (GBM) - Recent Pipeline Updates 142
Recurrent Glioblastoma Multiforme (GBM) - Dormant Projects 198
Recurrent Glioblastoma Multiforme (GBM) - Discontinued Products 199
Recurrent Glioblastoma Multiforme (GBM) - Product Development Milestones 200
Featured News & Press Releases 200
Jun 17, 2014: FDA Grants Fast Track Status To DNAtrix Drug DNX-2401 For Recurrent Glioblastoma 200
May 30, 2014: Threshold Announces Data From Ongoing Phase 1/2 Trial of TH-302 Plus Bevacizumab (Avastin) in Patients With Recurrent Glioblastoma 200
Apr 09, 2014: DelMar Pharmaceuticals VAL-083 Clinical Trial in GBM Demonstrates Continued and Promising Progress at AACR 201
Mar 06, 2014: SeeThruEquity Issues Update on DelMar Pharmaceuticals, Inc.'s VAL-083 Clinical Trial 202
Jan 13, 2014: Apogenix' APG101 Demonstrates Significant Prolongation of Overall Survival in Biomarker-Positive Patients in Phase II Trial for the Treatment of Recurrent Glioblastoma 202
Jan 07, 2014: Apogenix to Present Phase II Results with APG101 for the Treatment of Recurrent Glioblastoma at Biotech Showcase in San Francisco 203
Dec 23, 2013: ImmunoCellular Therapeutics Announces First Patient Receives Vaccine in Phase I Trial of Cancer Vaccine ICT-121 in Recurrent Glioblastoma 204
Dec 03, 2013: ImmunoCellular Therapeutics Expands Manufacturing Relationship with Progenitor Cell Therapy, LLC for Dendritic Cell Vaccines 205
Nov 27, 2013: VBL Therapeutics Receives FDA Fast Track Designation for Lead Compound VB-111 205
Nov 24, 2013: Celldex Therapeutics' Rindopepimut Demonstrates Promising Clinical Activity in Patients with EGFRvIII-positive Recurrent Glioblastoma at SNO 206
Appendix 210
Methodology 210
Coverage 210
Secondary Research 210
Primary Research 210
Expert Panel Validation 210
Contact Us 211
Disclaimer 211
Amgen Inc.
AstraZeneca PLC
Eli Lilly and Company
GlaxoSmithKline plc
Agenus, Inc.
Sangamo BioSciences, Inc.
ZIOPHARM Oncology, Inc.
Novartis AG
Eisai Co., Ltd.
Ono Pharmaceutical Co., Ltd.
Pfizer Inc.
GW Pharmaceuticals plc
Celldex Therapeutics, Inc.
ImmunoCellular Therapeutics, Ltd.
ThromboGenics NV
Spectrum Pharmaceuticals, Inc.
Virttu Biologics Limited
EnGeneIC Ltd
AngioChem Inc.
GenSpera, Inc.
Ascenta Therapeutics, Inc.
Vascular Biogenics Ltd.
Tocagen Inc.
Karyopharm Therapeutics, Inc.
ERC Belgium SA				
Full Name
Email
Job Title
Mobile
Your Requirement
Full Name
Email
Job Title
Mobile
Your Requirement